Critical role of MAO inhibition in Parkinson's disease.
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000201:enzymology; D012642:Selegiline / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D007980:Levodopa; D000109:Acetylcholine; D004298:Dopamine